.

Subscribe for Complete Access

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Argus Health
Novartis
Federal Trade Commission
Cipla
Baxter
Fish and Richardson
US Army
Julphar
Medtronic

Generated: July 28, 2017

DrugPatentWatch Database Preview

ORBACTIV Drug Profile

« Back to Dashboard

What is the patent landscape for Orbactiv, and when can generic versions of Orbactiv launch?

Orbactiv is a drug marketed by The Medicines Co and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and seventeen patent family members in thirty-seven countries.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.

Summary for Tradename: ORBACTIV

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list3
Clinical Trials: see list5
Patent Applications: see list7
Drug Prices:see details
DailyMed Link:ORBACTIV at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ORBACTIV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,843,889 Glycopeptide antibiotic derivatives► Subscribe
5,952,466 Reductive alkylation of glycopeptide antibiotics► Subscribe
5,977,062 Glycopeptide antibiotic derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ORBACTIV

Country Document Number Estimated Expiration
Spain2570401► Subscribe
Czech Republic292895► Subscribe
Colombia4650045► Subscribe
Argentina010621► Subscribe
Hong Kong1011542► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ORBACTIV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0834Netherlands► SubscribePRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
/2016Austria► SubscribePRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
2016 00044Denmark► SubscribePRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
AstraZeneca
Moodys
Medtronic
Queensland Health
Argus Health
Cantor Fitzgerald
Daiichi Sankyo
Julphar
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot